

IN THE SPECIFICATION:

Please insert the following sentence at the beginning of the specification:

*B* This application is a national entry of PCT/EP97/03712, filed on July 8, 1997.

Please insert the following paragraph on page 17, before the paragraph that begins "The present invention is further described by way of examples with reference to the accompanying figures, in which:"

*B* A kit that comprises a labeled peptide, or a peptide conjugated to a detectable marker, may be used. The detectable marker may be a radionuclide or other diagnostic marker known in the field.

IN THE CLAIMS:

*B* Please cancel claims 1, 6, 7, 23, 26, 27, 28, and 29 without prejudice or disclaimer.

*B* 2. (Twice amended) A peptide comprising at least part of the amino acid sequence of SEQ ID NO:9, wherein said original amino acid at position 2, threonine, is substituted with a valine, wherein said peptide is capable of inducing an increased binding affinity towards lymphocytes than said peptide comprising a threonine at position 2, and wherein said lymphocytes are directed against metastatic melanomas.

*B* 4. (Three times amended) A peptide comprising the amino acid sequence of SEQ ID NO:1, wherein said peptide is capable of inducing an increased binding affinity towards lymphocytes than a peptide comprising the amino acid sequence of SEQ ID NO:9, and wherein said lymphocytes are directed against metastatic melanomas.

*B* 11. (Three times amended) A method for isolating melanoma antigen reactive tumor infiltrating lymphocytes, said method comprising the steps of: